Aptevo Therapeutics (NASDAQ:APVO) Releases Earnings Results, Misses Estimates By $0.14 EPS

Posted by Jessica Moore on Nov 8th, 2025

Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) released its earnings results on Thursday. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($0.14), Zacks reports.

Aptevo Therapeutics Stock Performance

Aptevo Therapeutics stock remained flat at $1.47 during trading hours on Friday. 1,199,289 shares of the company’s stock traded hands, compared to its average volume of 2,424,141. The company has a market cap of $4.83 million, a price-to-earnings ratio of 0.00 and a beta of 5.93. The business’s 50-day simple moving average is $1.55 and its 200-day simple moving average is $3.58. Aptevo Therapeutics has a 12 month low of $1.32 and a 12 month high of $298.00.

Wall Street Analysts Forecast Growth

Several research firms have commented on APVO. Wall Street Zen raised shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Roth Capital upgraded shares of Aptevo Therapeutics to a “strong-buy” rating in a report on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Wednesday. Finally, Zacks Research raised shares of Aptevo Therapeutics to a “hold” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Aptevo Therapeutics has an average rating of “Hold”.

View Our Latest Report on Aptevo Therapeutics

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.